OC-0052: Late toxicity in the randomized phase III Dutch Hypofractionation Trial for prostate cancer patients (HYPRO)

Acute Toxicity of Hypofractionated Intensity-Modulated Radiotherapy for Prostate Cancer

“…Future analysis of data from phase i/ii studies will provide dose-volume histogram safety parameters for hfrt, with ranges of dose and fractionation. As already mentioned, hfrt in prostate cancer could offer a therapeutic advantage, but concerns have been raised that the delivery of fractions exceeding 2 Gy could potentially precipitate increased acute toxicity and subsequent late permanent side effects, as demonstrated in a recent Dutch trial, hypro, in which acute toxicity strongly predicted late toxicity 29,34 . Lock et al 22 also reported that acute gi toxicity of grade 2 or greater predicted late toxicity of grade 2 or greater (p < 0.001), and patients experiencing acute toxicity had an almost-tripled risk of late toxicity (32% vs. 12%, p = 0.0001).…”